Last reviewed · How we verify
Non-insulin anti-diabetic treatment
Non-insulin anti-diabetic treatment is a Small molecule drug developed by Sanofi. It is currently FDA-approved for Type 2 diabetes mellitus (multiple agents across various classes).
Non-insulin anti-diabetic treatments work through various mechanisms to lower blood glucose by enhancing insulin secretion, improving insulin sensitivity, reducing hepatic glucose production, or slowing carbohydrate absorption.
Non-insulin anti-diabetic treatments work through various mechanisms to lower blood glucose by enhancing insulin secretion, improving insulin sensitivity, reducing hepatic glucose production, or slowing carbohydrate absorption. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Non-insulin anti-diabetic treatment |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Sanofi manufactures multiple non-insulin anti-diabetic agents across different drug classes, including sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. Each class targets different pathways in glucose homeostasis to achieve glycemic control in type 2 diabetes mellitus. The specific mechanism depends on which individual agent within Sanofi's portfolio is being referenced.
Approved indications
- Type 2 diabetes mellitus (multiple agents across various classes)
Common side effects
- Hypoglycemia
- Gastrointestinal disturbances
- Weight changes
- Headache
Key clinical trials
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Quantifying Hepatic Mitochondrial Fluxes in Humans (PHASE4)
- A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin (PHASE3)
- A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before (PHASE3)
- Acute-to-chronic Glycemic Ratio (ACGR) is a Marker of DFUs .
- The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes
- Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea (PHASE4)
- Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non-insulin anti-diabetic treatment CI brief — competitive landscape report
- Non-insulin anti-diabetic treatment updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Non-insulin anti-diabetic treatment
What is Non-insulin anti-diabetic treatment?
How does Non-insulin anti-diabetic treatment work?
What is Non-insulin anti-diabetic treatment used for?
Who makes Non-insulin anti-diabetic treatment?
What development phase is Non-insulin anti-diabetic treatment in?
What are the side effects of Non-insulin anti-diabetic treatment?
Related
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus (multiple agents across various classes)
- Compare: Non-insulin anti-diabetic treatment vs similar drugs
- Pricing: Non-insulin anti-diabetic treatment cost, discount & access